Literature DB >> 15126237

C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats.

Martin J Stevens1, Weixian Zhang, Fei Li, Anders A F Sima.   

Abstract

Oxidative stress and neurovascular dysfunction have emerged as contributing factors to the development of experimental diabetic neuropathy (EDN) in streptozotocin-diabetic rodents. Additionally, depletion of C-peptide has been implicated in the pathogenesis of EDN, but the mechanisms of these effects have not been fully characterized. The aims of this study were therefore to explore the effects of diabetes on neurovascular dysfunction and indexes of nerve oxidative stress in type 1 bio-breeding Worcester (BB/Wor) rats and type 2 BB Zucker-derived (ZDR)/Wor rats and to determine the effects of C-peptide replacement in the former. Motor and sensory nerve conduction velocities (NCVs), hindlimb thermal thresholds, endoneurial blood flow, and indicators of oxidative stress were evaluated in nondiabetic control rats, BB/Wor rats, BB/Wor rats with rat II C-peptide replacement (75 nmol C-peptide.kg body wt(-1).day(-1)) for 2 mo, and diabetes duration-matched BBZDR/Wor rats. Endoneurial perfusion was decreased and oxidative stress increased in type 1 BB/Wor rats. C-peptide prevented NCV and neurovascular deficits and attenuated thermal hyperalgesia. Inhibition of nitric oxide (NO) synthase, but not cyclooxygenase, reversed the C-peptide-mediated effects on NCV and nerve blood flow. Indexes of oxidative stress were unaffected by C-peptide. In type 2 BBZDR/Wor rats, neurovascular deficits and increased oxidative stress were unaccompanied by sensory NCV slowing or hyperalgesia. Therefore, nerve oxidative stress is increased and endoneurial perfusion decreased in type 1 BB/Wor and type 2 BBZDR/Wor rats. NO and neurovascular mechanisms, but not oxidative stress, appear to contribute to the effects of C-peptide in type 1 EDN. Sensory nerve deficits are not an inevitable consequence of increased oxidative stress and decreased nerve perfusion in a type 2 diabetic rodent model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126237     DOI: 10.1152/ajpendo.00048.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  31 in total

1.  Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Authors:  Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova
Journal:  Exp Neurol       Date:  2011-04-16       Impact factor: 5.330

2.  Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.

Authors:  Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  C-peptide is a bioactive peptide.

Authors:  J Wahren; K Ekberg; H Jörnvall
Journal:  Diabetologia       Date:  2007-01-18       Impact factor: 10.122

Review 4.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

5.  Will C-peptide substitution make a difference in combating complications in insulin-deficient diabetes?

Authors:  Anders A F Sima
Journal:  Rev Diabet Stud       Date:  2004-08-10

6.  Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.

Authors:  Irina G Obrosova; Viktor R Drel; Pal Pacher; Olga Ilnytska; Zhong Q Wang; Martin J Stevens; Mark A Yorek
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

Review 7.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

8.  Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes.

Authors:  Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan A Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Seth R Bell; John T Groves; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2007-12       Impact factor: 4.101

Review 9.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 10.  Alternatives to the Streptozotocin-Diabetic Rodent.

Authors:  M A Yorek
Journal:  Int Rev Neurobiol       Date:  2016-03-28       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.